Xeris Biopharma Holdings, Inc. (XERS) Total Assets by Year
Xeris Biopharma Holdings, Inc. closed fiscal year 2025 with $383.5M in total assets, $369.8M in total liabilities and $13.7M in shareholder equity. This represents an increase of 18.7% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Xeris Biopharma Holdings, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
XERS Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|---|---|---|
| Total Assets | $383.5M+18.7% | $323.1M+0.1% | $322.6M-6.4% | $344.5M+13.2% | $304.4M+91.2% | $159.2M |
| Total Liabilities | $369.8M+4.9% | $352.7M+7.1% | $329.4M+10.0% | $299.3M+43.1% | $209.1M+66.8% | $125.4M |
| Total Equity | $13.7M+146.2% | -$29.6M-336.7% | -$6.8M-115.0% | $45.2M-52.6% | $95.2M+182.1% | $33.8M |
XERS Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $411.9M+23.1% | $392.0M+24.3% | $383.5M+18.7% | $370.2M+15.3% | $334.7M+0.9% | $315.5M-6.3% | $323.1M+0.1% | $321.1M-2.0% | $331.7M+0.9% | $336.6M+4.7% | $322.6M-6.4% | $327.8M+8.2% |
| Total Liabilities | $421.6M+19.1% | $379.0M+8.1% | $369.8M+4.9% | $371.1M+6.2% | $354.0M+0.8% | $350.6M+1.4% | $352.7M+7.1% | $349.4M+7.9% | $351.0M+11.4% | $345.8M+18.7% | $329.4M+10.0% | $323.9M+30.6% |
| Total Equity | -$9.7M+49.6% | $13.0M+137.0% | $13.7M+146.2% | -$861K+97.0% | -$19.3M-0.1% | -$35.1M-282.7% | -$29.6M-336.7% | -$28.3M-832.8% | -$19.3M-241.4% | -$9.2M-130.5% | -$6.8M-115.0% | $3.9M-93.0% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Xeris Biopharma Holdings, Inc. financials
Frequently Asked Questions
What was Xeris Biopharma Holdings, Inc.'s total assets in fiscal year 2025?
Xeris Biopharma Holdings, Inc. closed fiscal year 2025 with $383.5M in total assets, $369.8M in total liabilities and $13.7M in shareholder equity.
How fast is Xeris Biopharma Holdings, Inc.'s total assets growing?
Xeris Biopharma Holdings, Inc. (XERS) total assets rose by 18.7% year over year, from $323.1M to $383.5M in fiscal year 2025.
How has Xeris Biopharma Holdings, Inc.'s total assets changed over the years?
Across the 6 fiscal years this page covers, Xeris Biopharma Holdings, Inc. (XERS) total assets went from $159.2M in fiscal year 2020 to $383.5M in fiscal year 2025.
What was Xeris Biopharma Holdings, Inc.'s total assets in the most recent quarter?
Xeris Biopharma Holdings, Inc. (XERS) reported $411.9M in total assets in Q2 2026. This represents an increase of 23.1% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Xeris Biopharma Holdings, Inc. (XERS) reported on that line in every period on record.